Cortechs.ai | Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant<sup>®</sup>

Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant®

Cortechs.ai expands market reach into Canada for NeuroQuant, the leading volumetric brain imaging solution for MRIs.

(SAN DIEGO) Feb. 2, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that it has received Health Canada/Santé Canada Medical Device License for marketing and distribution of NeuroQuant® in Canada. Already FDA cleared and CE marked, NeuroQuant is used throughout the world by physicians in hundreds of reputable clinics and hospitals to help in their assessment of neurodegeneration.

Fully automated, NeuroQuant provides neurologists, radiologists, and clinical researchers with an accurate and convenient tool to quantify the volumes of specific brain structures in order to better assess neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

“The Heath Canada/Santé Canada Medical Device License is a testament to our commitment to quality, safety and performance and now allows customers in Canada to start using NeuroQuant in their clinical practice,” commented Guri Stark, CEO of Cortechs.ai. “We are excited to introduce our innovative brain imaging solution to Canadian hospitals, clinics and universities and expand access to proven and reliable quantitative volumetric analysis of neurological conditions via MR imaging.”

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of MRI images of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

06/16/2025

Seeing Alzheimer’s More Clearly: How PET Imaging Is Changing the Game

PET imaging is transforming how we detect and monitor Alzheimer’s disease, enabling earlier diagnosis, better disease tracking, and more personalized treatment.

06/11/2025

Cortechs.ai and RMS Medical Devices Forge Distribution Partnership to Expand Access to AI-Powered Imaging Solutions in the Benelux Region

We’re excited to announce our new partnership with RMS Medical Devices to our advanced neuroimaging and prostate imaging solutions to the Benelux region

06/04/2025

Cortechs.ai and deepc Announce Strategic Partnership to Advance AI Integration in Radiology

Press Release: Delivering Clinically Validated AI Solutions for Enhanced Imaging Precision and Workflow Efficiency

05/29/2025

Enhancing Imaging Workflow with DICOM SR: NeuroQuant®’s Seamless Integration 

As imaging becomes more data-driven, tools like NeuroQuant® with DICOM SR support pave the way for smarter, more connected radiology

05/18/2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer’s Disease Care Through AI-Driven Imaging

This new strategic collaboration aims to enhance the quality of care for people living with Alzheimer’s disease.

05/16/2025

Case Study: NeuroQuant® for ARIA: Monitoring ARIA Progression in Early Alzheimer’s Disease

Dr. Suzie Bash highlights how advanced imaging with NeuroQuant for ARIA supported detection and monitoring of ARIA-E and ARIA-H in an 81-year-old patient.
Scroll to Top